149 related articles for article (PubMed ID: 36320663)
41. Global Distribution, Dispersal Patterns, and Trend of Several Omicron Subvariants of SARS-CoV-2 across the Globe.
Kopsidas I; Karagiannidou S; Kostaki EG; Kousi D; Douka E; Sfikakis PP; Moustakidis S; Kokkotis C; Tsaopoulos D; Tseti I; Zaoutis T; Paraskevis D
Trop Med Infect Dis; 2022 Nov; 7(11):. PubMed ID: 36422924
[TBL] [Abstract][Full Text] [Related]
42. Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding.
Popovic M
BioTech (Basel); 2022 Oct; 11(4):. PubMed ID: 36278557
[TBL] [Abstract][Full Text] [Related]
43. The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity.
DeGrasse DC; Black SD
Cureus; 2023 Jun; 15(6):e40148. PubMed ID: 37313287
[TBL] [Abstract][Full Text] [Related]
44. Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages.
Tahsin A; Ahmed R; Bhattacharjee P; Adiba M; Al Saba A; Yasmin T; Chakraborty S; Hasan AKMM; Nabi AHMN
Comput Biol Med; 2022 Sep; 148():105903. PubMed ID: 35932731
[TBL] [Abstract][Full Text] [Related]
45. Identification of SARS-CoV-2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021.
Subramoney K; Mtileni N; Bharuthram A; Davis A; Kalenga B; Rikhotso M; Maphahlele M; Giandhari J; Naidoo Y; Pillay S; Ramphal U; Ramphal Y; Tegally H; Wilkinson E; Mohale T; Ismail A; Mashishi B; Mbenenge N; de Oliveira T; Makatini Z; Fielding BC; Treurnicht FK;
J Med Virol; 2022 Aug; 94(8):3676-3684. PubMed ID: 35441368
[TBL] [Abstract][Full Text] [Related]
46. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
Zhu Y; Hu Y; Liu N; Chong H; He Y
Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
[TBL] [Abstract][Full Text] [Related]
47. Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1 and BA.2 have higher stability.
Hirose R; Itoh Y; Ikegaya H; Miyazaki H; Watanabe N; Yoshida T; Bandou R; Daidoji T; Nakaya T
Clin Microbiol Infect; 2022 Nov; 28(11):1486-1491. PubMed ID: 35640841
[TBL] [Abstract][Full Text] [Related]
48. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Ohashi H; Hishiki T; Akazawa D; Kim KS; Woo J; Shionoya K; Tsuchimoto K; Iwanami S; Moriyama S; Kinoshita H; Yamada S; Kuroda Y; Yamamoto T; Kishida N; Watanabe S; Hasegawa H; Ebihara H; Suzuki T; Maeda K; Fukushi S; Takahashi Y; Iwami S; Watashi K
Antiviral Res; 2022 Sep; 205():105372. PubMed ID: 35798223
[TBL] [Abstract][Full Text] [Related]
49. The First Identification in Italy of SARS-CoV-2 Omicron BA.4 Harboring KSF141_del: A Genomic Comparison with Omicron Sub-Variants.
Peronace C; Tallerico R; Colosimo M; Fazio M; Pasceri F; Talotta I; Panduri G; Pintomalli L; Oteri R; Calantoni V; Fiorillo MT; Caroleo MC; Curcio R; Dolce V; Cione E; Minchella P
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009386
[TBL] [Abstract][Full Text] [Related]
50. Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China.
Sun Y; Wang M; Lin W; Dong W; Xu J
J Biosaf Biosecur; 2023 Mar; 5(1):14-20. PubMed ID: 36718149
[TBL] [Abstract][Full Text] [Related]
51. Convolutional Neural Networks Based on Sequential Spike Predict the High Human Adaptation of SARS-CoV-2 Omicron Variants.
Nan BG; Zhang S; Li YC; Kang XP; Chen YH; Li L; Jiang T; Li J
Viruses; 2022 May; 14(5):. PubMed ID: 35632811
[TBL] [Abstract][Full Text] [Related]
52. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2.
Hu B; Chan JF; Liu H; Liu Y; Chai Y; Shi J; Shuai H; Hou Y; Huang X; Yuen TT; Yoon C; Zhu T; Zhang J; Li W; Zhang AJ; Zhou J; Yuan S; Zhang BZ; Yuen KY; Chu H
Emerg Microbes Infect; 2022 Dec; 11(1):2275-2287. PubMed ID: 36039901
[TBL] [Abstract][Full Text] [Related]
53. Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review.
K A; Sharma A; Kumar D; Singh SK; Gupta G; Chellappan DK; Dua K; Nagraik R
J Med Virol; 2022 Oct; 94(10):4628-4643. PubMed ID: 35705439
[TBL] [Abstract][Full Text] [Related]
54. Emergence of a SARS-CoV-2 Omicron Subvariant BA.2.2 with a 454-Nucleotide Genomic Deletion - Sichuan Province, China, May 10, 2022.
Feng Y; Zhao X; Luo T; Chen Z; Yang H; Chen N; Ma X; Li M; Zhang W; Jia S; Yuan X; Pan M; Zhou L
China CDC Wkly; 2022 Oct; 4(40):904-906. PubMed ID: 36285323
[No Abstract] [Full Text] [Related]
55. SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences.
Wang X; Lu L; Jiang S
Trends Immunol; 2024 Feb; 45(2):81-84. PubMed ID: 38302341
[TBL] [Abstract][Full Text] [Related]
56. Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion.
Al-Zyoud W; Haddad H
Virology; 2022 Aug; 573():84-95. PubMed ID: 35732100
[TBL] [Abstract][Full Text] [Related]
57. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
[TBL] [Abstract][Full Text] [Related]
58. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
Xiang T; Wang J; Zheng X
Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
[TBL] [Abstract][Full Text] [Related]
59. Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1-BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa.
Johnson R; Mangwana N; Sharma JR; Muller CJF; Malemela K; Mashau F; Dias S; Ramharack P; Kinnear C; Glanzmann B; Viraragavan A; Louw J; Surujlal-Naicker S; Nkambule S; Webster C; Mdhluli M; Gray G; Mathee A; Preiser W; Vorster A; Dalvie S; Street R
J Infect Dis; 2022 Oct; 226(8):1418-1427. PubMed ID: 36017801
[TBL] [Abstract][Full Text] [Related]
60. An Early and Preliminary Assessment of the Clinical Severity of the Emerging SARS-CoV-2 Omicron Variants in Maharashtra, India.
Karyakarte RP; Das R; Taji N; Yanamandra S; Shende S; Joshi S; Karekar B; Bawale R; Tiwari R; Jadhav M; Sakalkar S; Chaudhari G; Rane S; Agarasen J; Pillai P; Dudhate S; Chandankhede P; Labhshetwar R; Gadiyal Y; Rajmane M; Mukade S; Kulkarni P
Cureus; 2022 Nov; 14(11):e31352. PubMed ID: 36514661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
